TBSGC has achieved significant milestones in genome engineering such as the ORBIT method and optimization of recombineering techniques, enhancing core capabilities and enabling swift and selective genome modifications in Mtb, reflecting a commitment to advancing TB research and fostering transformative breakthroughs.
Our GOALS
We aim to investigate fundamental biological mechanisms determining drug synergy in Mtb, define structural relationships between novel targets and chemical inhibitors for potential combination therapeutics, integrate drug interaction synergy into early drug discovery, determine structures of membrane proteins involved in drug mode of action, and discover early-stage chemical inhibitors synergistic with existing TB treatments and new therapeutics. Ultimately, the goal is to shift TB drug development towards targets and compounds likely to yield more effective combination regimens.
Each project is dedicated to exploring aspects of Mtb physiology characterized by established synergistic relationships.